Human Umbilical Cord Mesenchymal Stem Cells Preserve Adult Newborn Neurons and Reduce Neurological Injury after Cerebral Ischemia by Reducing the Number of Hypertrophic Microglia/Macrophages

Willie Lin¹, Yogi Chang-Yo Hsuan¹, Mao-Tsun Lin², Ting-Wei Kuo³, Cheng-Hsien Lin¹, Yu-Chin Su¹, Ko-Chi Niu⁴, Ching-Ping Chang²,³,⁵, and Hung-Jung Lin³,⁶

Abstract
Microglia are the first source of a neuroinflammatory cascade, which seems to be involved in every phase of stroke-related neuronal damage. Two weeks after transient middle cerebral artery occlusion (MCAO), vehicle-treated rats displayed higher numbers of total ionized calcium-binding adaptor molecule 1 (Iba-1)-positive cells, greater cell body areas of Iba-1-positive cells, and higher numbers of hypertrophic Iba-1-positive cells (with a cell body area over 80 \( \mu \text{m}^2 \)) in the ipsilateral ischemic brain regions including the frontal cortex, striatum, and parietal cortex. In addition, MCAO decreased the number of migrating neuroblasts (or DCX- and 5-ethyl-2'-deoxyuridine-positive cells) in the cortex, subventricular zone, and hippocampus of the ischemic brain, followed by neurological injury (including brain infarct and neurological deficits). Intravenous administration of human umbilical cord–derived mesenchymal stem cells (hUC-MSCs; 1 \( \times 10^6 \) or 4 \( \times 10^6 \)) at 24 h after MCAO reduced neurological injury, decreased the number of hypertrophic microglia/macrophages, and increased the number of newborn neurons in rat brains. Thus, the accumulation of hypertrophic microglia/macrophages seems to be detrimental to neurogenesis after stroke. Treatment with hUC-MSCs preserved adult newborn neurons and reduced functional impairment after transient cerebral ischemia by reducing the number of hypertrophic microglia/macrophages.

Keywords
stroke, microglia, umbilical cord mesenchymal stem cells, cell therapy

Introduction
Ischemic stroke, a focal cerebral insult, leads to adverse neurological complications or behavioral disorders. Over the next decades, the prevalence of ischemic stroke is expected to increase.¹ To date, the only approved therapy, vessel recanalization by recombinant tissue plasminogen activator, is limited by a narrow time window¹ and serious complications...
such as hemorrhage. Consequently, alternative strategies are in high demand. Among these strategies, transplantation of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) via intravenous administration seems promising. hUC-MSCs improve ischemic stroke outcomes by enhancing neurite remodeling, neurogenesis, and angiogenesis. However, the neuroprotective mechanisms underlying hUC-MSC therapy remain unclear.

Cerebral ischemia transforms the morphology of microglia or macrophages from the resting ramified phenotype into the hypertrophic (or activated amoeboid) phenotype. Moreover, following ischemic stroke, neuroblasts generated in the subventricular zone (SVZ) also migrate into the striatum and cerebral cortex. In rodents, microglial activation is detrimental to newly formed hippocampal neurons. In an ischemic stroke animal model, resting ramified microglia promote neurogenesis, whereas activated hypertrophic microglia impair neurogenesis. Thus, hUC-MSC therapy may preserve adult newborn neurons and reduce neurological injury after cerebral ischemia by reducing the number of hypertrophic microglia/macrophages.

To test our hypothesis, we first quantified changes in the total numbers of microglia/macrophages (or ionized calcium-binding adaptor molecule 1 [Iba-1]-positive cells) in the rat brain following a transient ischemic stroke. Then, we used the cell body areas of Iba-1-positive cells in the ischemic brain region to determine the numbers of hypertrophic or amoeboid microglia. In addition, the number of doublecortin (DCX)- and bromodeoxyuridine-specific cells in the brain represents the number of newborn neurons. Therefore, in the present study, we ascertained whether hUC-MSCs administered intravenously improved the outcomes of ischemic stroke by modulating the number of both hypertrophic microglia/macrophages and newborn neurons.

Materials and Methods

Isolation of hUC-MSCs and Culture of hUC-MSCs

hUC-MSCs were obtained from Meridigen Biotech Co., Ltd. (Taipei, Taiwan). The participants and their families were informed of the experiment and signed informed consent forms. The study protocol was approved by the Ethics Committee for Clinical Research at the Chi Mei Medical Center (institutional review board no. 10405-008).

Umbilical cord tissue was harvested under sterile conditions and digested with collagenase in a 37 °C incubator. The digestion was terminated with culture medium. The cells were then incubated in a humidified incubator with 5% CO2 at 37 °C for 3 d, at which point, the culture medium was replenished, and the nonadherent cells (hUC-MSCs) were suspended in CryoStor® CS 10 (STEMCELL Technologies, Vancouver, BC, Canada) and cryopreserved in a vapor phase liquid nitrogen tank for long-term storage.

hUC-MSC Identification, Differentiation, and Preparation

Flow cytometry analysis revealed the expression of specific surface antigens on the hUC-MSCs; the hUC-MSCs were positive for CD44, CD73, CD90, CD105, and ephrin type-A receptor 2 and negative for CD34, CD45, CD19, CD11b, and Human Leukocyte Antigen-antigen D Related (HLADR). Antibodies for flow cytometry were obtained from BD Biosciences (San Diego, CA, USA). hUC-MSCs were also analyzed for their ability to differentiate into osteoblasts, adipocytes, and chondrocytes. After the hUC-MSCs reached 80% confluence, they were freshly harvested for an animal study. Briefly, hUC-MSCs were trypsinized for 2 min at 37 °C and neutralized by complete culture medium. The cell suspension was centrifuged at 300 relative centrifugal force (RCF) for 5 min. After the final wash, cell viability was assessed using 0.4% trypan blue in a Neubauer counting chamber to exclude dead cells and to ensure an adequate number of vital cells for transplantation. The supernatant was aspirated, and the cell pellet was resuspended in normal saline (NS). The final concentration was adjusted to 1 × 10⁶ cells/mL or 4 × 10⁶ cells/mL. Each umbilical cord (35 mL volume) contained 1.2 × 10⁸ cells. The viability of these cord cells was above 95%.

Experimental Groups

The animals were randomly divided into experimental groups. The sham surgery group received an intravenous...
dose of NS (1 mL/kg of body weight) or hUC-MSCs (4 × 10^6 cells/mL) 24 h after sham surgery (sham + NS or sham + hUC-MSCs 4 × 10^6), and the MCAO group received an intravenous dose of NS (MCAO + NS) or hUC-MSCs (4 × 10^6 cells/mL/kg of body weight) 24 h after surgery (MCAO + hUC-MSCs 4 × 10^6). The stroke animals were intravenously injected with NS or hUC-MSCs suspended in NS 24 h after stroke.

**Functional Outcome**

Modified neurologic severity scores (mNSSs) were used to assess the motor, sensory, reflex, and balance function of all rats at 1 d before surgery and at 1, 7, and 14 d after surgery. Baseline readings at 1 d before surgery were used as the internal controls. All behavioral experiments were performed between 9 AM and 2 PM.

We used an inclined plane system with a microcontroller to determine the limb motor function of the rats. The rat was placed, facing right and then left, perpendicular to the scope of a 20 × 20 cm^2 rubber, ribbed surface of an inclined plane starting at an angle of 55°. The angle was increased or decreased in 5° increments to determine the maximal angle at which a rat could hold onto the plane.

The adhesive removal test was used to analyze both forepaw sensitivity, including the presence of neglect, and forepaw motor impairments. The rats were placed in a transparent box for 1 min for habituation. Next, the rat was removed from the box, and 1 strip of adhesive tape was attached to each of the rat’s paws. The rat was then placed into the box again. For a total of 120 s, the investigators calculated the time to either contact or remove the adhesive tape.

A modified forelimb foot fault placing test was used to examine forelimb function. If the rats inaccurately placed a forelimb, the limb would fall through one of the openings in the grid. These mistakes were considered foot faults. The rats displayed better forelimb function if they made fewer errors during this test.

**Assessment of Infarct Size**

Triphenyl tetrazolium chloride (Sigma-Aldrich) staining procedures were used to assess cerebral infarct size. To avoid the impact of liquefaction and atrophy after infarction, we modified previous methods used for quantification of infarction volume in rats subjected to MCAO and used these methods to assess infarct size in the present study. We defined the infarct area as the normally stained (red color) area in the contralateral hemisphere minus the normally stained area in the ipsilateral hemisphere. Infarction volume was calculated as the sum of the infarct area across all brain sections, multiplied by the section thickness (1 mm). The corrected infarct volume (CIV) was calculated by the following equation:

\[ \text{CIV} = (\text{LT} - \text{RNIA}) \times d, \]

where LT is the area of the left (i.e., contralateral) hemisphere, RNIA is the right (i.e., ipsilateral) hemisphere (non-infarcted area), and d is the slice thickness (1 mm).

**Randomization and Full Blinding**

The animals were housed 4 per cage and identified by a number printed on the base of the tail. In each cage, 2 rats were randomly assigned to a vehicle group and the others to an MSC treatment group. Two individuals who were responsible for the functional outcome measurements were the only 2 experimenters blinded to the treatments among those working on the animals (single blind). These individuals used the cage and animal codes to recognize individuals and to report repeated measurements on data collection forms.

**Assessment of Endogenous Stem Cell Proliferation**

To evaluate cell proliferation, the rats received an intraperitoneal injection of a cell proliferation–specific marker 5-ethynyl-2'-deoxyuridine (EdU, 10 mg/kg; Invitrogen Life Technologies, Rockford, IL, USA) once daily, starting at day 1 after stroke and continuing for 14 d. The animals were euthanized at 14 d post-MCAO and perfused with 4% paraformaldehyde in phosphate-buffered saline (PBS).

**Histology and Immunohistochemistry**

Coronal paraffin sections (10 μm) were washed twice with PBS and incubated with primary antibodies at 4 °C overnight and with secondary antibodies in blocking solution at room temperature for 2 h. For cell proliferation analysis, the sections were incubated with antidoublecortin (DCX; Cell Signaling Technology, Inc., Danvers, MA, USA) and/or antineuronal nuclei (NeuN; Millipore Corporation, Billerica, MA, USA) antibodies. Immunoreactivity was visualized using Alexa Fluor 568–conjugated goat antimouse IgG (Invitrogen Life Technologies, Rockford, IL, USA) or Alexa Fluor 568–conjugated goat antirabbit IgG (Invitrogen Life Technologies, Rockford, IL, USA) secondary antibodies. Labeling for EdU was performed using a Click-iT® EdU Alexa Fluor® 488 Imaging Kit according to the manufacturer’s instructions (Thermo Fisher Scientific, Inc., Eugene, OR, USA). The primary and secondary antibodies used for immunohistochemical staining are listed in Tables 1 and 2.

The sections were mounted with VECTASHIELD mounting medium (Vector Laboratories, Burlingame, CA, USA), and fluorescence signals were detected with a Carl Zeiss upright fluorescence microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) at excitation/emission wavelengths of 535/565 nm (rhodamine, red) and 470/505 nm (fluorescein isothiocyanate (FITC), green). A digital camera linked to a computer running AxioScope version 4 (Carl Zeiss) was used to capture images.

For quantification of the total numbers of Iba-1-positive cells, every tenth 5-μm-thick section corresponding to coronal
coordinates 4.2 mm anterior to bregma to 5.3 mm posterior to bregma was obtained and incubated in 2 mol/L hydrogen chloride for 30 min, rinsed in 0.1 mol/L boric acid (H3BO3; pH 8.5) for 3 min at room temperature, and then incubated with a rabbit anti-Iba-1 antibody (GeneTex Inc., San Antonio, TX, USA) at 4 °C overnight. After the sections were washed with PBS, each section was incubated with N-Histofine Simple Stain MAX PO (Nichirei Biosciences Inc., Tokyo, Japan) as a secondary antibody at room temperature for 60 min. Binding of the primary antibody was visualized using 3-amino-9-ethylcarbazole (AEC) in acetate buffer (BioGenex, San Ramon, CA, USA). The numbers of Iba-1-positive cells were counted throughout the cortical, striatal, SVZ, hippocampal, and hypothalamic fields of the ischemic core and boundary area. Images of the red–brown–immunohistochemical staining of immune cells were captured with a 20 × oil immersion objective (numerical aperture [N.A.] 1.4) using an upright microscope system (Carl Zeiss) and counted using Axio Vision Image analysis software V4.8.1 (Carl Zeiss).

We modified the methodology of Resende et al.¹⁰ to assess the cell body (soma) size of microglia. Sequences of 10 immunostained sections per region per rat were examined with a 100 × oil immersion objective (N.A. 1.4) and Zen Software V2.3 (Carl Zeiss). Each microglial cell body was outlined using a contour tool and expressed in square micrometer. The average of microglial cell body areas were calculated for the frontal cortex (4.2 mm anterior to bregma to 1.7 mm anterior to bregma), striatum (1.7 mm anterior to bregma to 0.8 mm posterior to bregma), and parietal cortex (1 mm posterior to bregma to 4.5 mm posterior to bregma). As shown in Fig. 1C, any Iba-1-positive cell with a cell body area above 80 μm² was defined as a hypertrophic or amoeboid microglial cell. An observer blinded to the exposure groups quantified the total number of activated microglia, determined by a cell body area above 80 μm², as well as the total number of resting ramified microglia (with a cell body area below 80 μm²). The counts obtained from 3 different images per section were averaged. The results are expressed as a percentage of activated microglia or total number of microglia in the analyzed regions of interest.

For quantification of neuronal apoptosis, coronal cryosections (10 μm thick) from the animals of each group were stained with a terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay kit (Clontech, Palo Alto, CA, USA). The sections were counterstained with 4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Negative controls without the primary antibody revealed no positive signals (data not shown). Two independent investigators evaluated all immunohistochemical staining. The total numbers of NeuN-positive cells and NeuN/DAPI/TUNEL triple-labeled cells were calculated in 5 coronal sections from each rat, counted for at least 10 rats per group, and expressed as the mean number of cells per section.

**Statistics**

Two-way analysis of variance (ANOVA) with Tukey’s post hoc test or Bonferroni post hoc test was used to analyze the percentage of infarct area and behavioral performance, respectively. Histological measures were analyzed using one-way ANOVA with Bonferroni posttests. All data are expressed as the mean ± standard deviation. Statistical significance was considered P < 0.05 according to standard conventions and was indicated by single symbols (* and +).

**Results**

**hUC-MSCs Attenuate Infarct Volume**

Compared with the sham + NS group or sham + hUC-MSC 4 × 10⁶ group, the MCAO + NS group had significantly larger cerebral infarct volumes (Fig. 2). However, compared with the MCAO + NS group, the MCAO + hUC-MSC 1 × 10⁶ and MCAO + hUC-MSC 4 × 10⁶ groups had lower cerebral infarct

---

**Table 1.** Antibodies Used for Immunofluorescence Staining.

| Antibody                        | Antigen   | Host     | Company       | Catalog Number | Dilution |
|---------------------------------|-----------|----------|---------------|----------------|----------|
| Primary antibody                |           |          |               |                |          |
| NeuN                            | Neuron    | Mouse    | Millipore     | MAB377         | 1:200    |
| Doublecortin (DCX)              | Neuroblast| Rabbit   | Cell Signaling| 4604           | 1:200    |
| Iba-1                           | Microglia | Rabbit   | GeneTex       | GTX100042      | 1:200    |
| Secondary antibody (conjugation)|           |          |               |                |          |
| Goat antirabbit IgG (Alexa Fluor 568) | Rabbit IgG | Goat | Invitrogen | A11011 | 1:400    |
| Goat antimouse IgG (Alexa Fluor 568) | Mouse IgG | Goat | Invitrogen | A11004 | 1:400    |

**Table 2.** Immunohistochemistry Staining Kits.

| Kit                             | Company | Catalog Number |
|---------------------------------|---------|----------------|
| DNA Fragmentation Assay Kit     | Clontech| 630108         |
| (terminal deoxyribonucleotide transferase-mediated dUTP nick end labeling kit) | | |
| EdU (5-ethyl-2'-deoxyuridine)   | Invitrogen | E10415 |
| Click-IT EdU Alexa Fluor 488 Imaging Kit | Invitrogen | C10337 |
| N-Histofine Simple Stain MAX PO (MULTI) | Nichirei Biosciences | 41415F |
| AEC Substrate Pack              | BioGenex | HK092-5K       |

Abbreviations: MULTI, this kit can be used in rat and mouse species; AEC, 3-amino-9-ethylcarbazole.
volumes (Fig. 2). The results revealed that hUC-MSC therapy attenuated MCAO-induced cerebral infarct. However, the beneficial effects of hUC-MSCs $4 \times 10^6$ on brain infarct reduction were not superior to those of hUC-MSCs $1 \times 10^6$.

**hUC-MSCs Promote Neurological Motor Functional Recovery**

Compared with the sham + NS group, the MCAO + NS group had a lower maximal angle (in the inclined test), a higher error ratio (in the forelimb foot fault placing test), a higher mNSS, and a higher number of seconds (in the adhesive removal test; Fig. 3). However, compared with the MCAO + NS group, the MCAO + hUC-MSC $1 \times 10^6$ group or MCAO + hUC-MSC $4 \times 10^6$ group had a higher maximal angle, a lower error ratio, a lower mNSS, and a lower number of seconds. The results revealed that hUC-MSC therapy attenuated ischemic stroke–induced neurological motor deficits. The beneficial effects of hUC-MSCs persisted up to day 14 poststroke. In the following studies, only the $4 \times 10^6$ hUC-MSC dosage was used.

**hUC-MSCs Reduce Neuronal Apoptosis and Loss**

Compared with the sham + NS group, the MCAO + NS group exhibited significantly lower numbers of neurons (or NeuN-positive cells) as well as significantly higher numbers of apoptotic neurons (or NeuN+ TUNEL-positive cells) in ipsilateral brain regions including the cortex and striatum (Fig. 4). However,
compared with the MCAO + NS group, the MCAO + hUC-MSC 4 × 10⁶ group had significantly higher numbers of neurons and significantly lower numbers of apoptotic neurons in ipsilateral brain regions (Fig. 4). The results revealed that hUC-MSC therapy reduced MCAO-induced neuronal loss and neuronal apoptosis.

**hUC-MSCs Promote Neuron Proliferation**

Compared with the MCAO + NS group, the MCAO + hUC-MSC 4 × 10⁶ group had significantly higher numbers of proliferating neurons (or NeuN- and EdU-positive cells) in ipsilateral brain regions including the frontal cortex, SVZ, parietal cortex, and hippocampus (Fig. 5). Double immunofluorescence staining revealed that treatment with hUC-MSCs significantly augmented the numbers of NeuN-EdU-positive cells in the cerebral cortex, SVZ, and hippocampus in rats 14 d after stroke (Fig. 5). The results revealed that hUC-MSC therapy promoted neuron proliferation in ipsilateral injured brain regions.

**hUC-MSCs Promote the Proliferation of Neuroblasts**

Again, compared with the MCAO + NS group, the MCAO + hUC-MSC 4 × 10⁶ group had significantly higher numbers of proliferating neuroblasts (or DCX-EdU-positive cells) in ipsilateral brain regions including the cortex, striatum, SVZ, parietal cortex, and hippocampus (Fig. 6). The results revealed that hUC-MSC therapy stimulated neuroblast proliferation in various brain regions.

**hUC-MSCs Attenuate Microglial Activation**

Immunohistochemistry revealed that compared with the sham + NS group, the MCAO + NS group had higher numbers of both total Iba-1-positive cells (microglia or macrophages; Fig. 1B) and larger cell body areas (Fig. 1C) in the ipsilateral frontal cortex, striatum, and parietal cortex (Fig. 1). As shown in Fig. 1C, the average cell body areas for the ramified microglia and hypertrophic microglia were 75 to 85 μm² and 140 to 150 μm², respectively. Based on the assumption that any Iba-1-positive cell with a cell body area above 80 μm² was a hypertrophic microglial cell, the MCAO + NS group had a significantly higher percentage of hypertrophic or amoeboid Iba-1-positive cells in the ipsilateral frontal cortex, striatum, and parietal cortex than the sham + NS group (Fig. 1D). MCAO-induced accumulation of total Iba-1-positive cells, larger cell body areas of Iba-1-positive cells, and accumulation of hypertrophic Iba-1-positive cells in the ischemic brain regions were all attenuated by hUC-MSCs but not by NS therapy (Fig. 1).

**Discussion**

MSCs Derived from Human Umbilical Cord Tissue or Cord Blood Are Expected to Be a Promising Tool for Acute Stroke Therapy

Different routes of administration include intraperitoneal, intravenous, and intraarterial injections. Because of its convenience, intravenous is the most common method in
In 2001, intravenous administration of human umbilical cord blood cells (hUCBCs) produced the greatest recovery when administered 24 h poststroke in rodents. In 2012, Boltze and colleagues further demonstrated that hUCBCs administered within a 72-h time window attenuated neurological dysfunction, brain atrophy, and glial scarring in stroke rats. In the present study, MSCs derived from human umbilical cords at 24 h poststroke attenuated neurological impairment (evidenced by neurological deficits, cerebral infarct, and neuronal apoptosis) in rats. These 3 independent laboratories have demonstrated the beneficial effects of hUCBCs or hUC-MSCs administered within 72 h after MCAO. In this study, we investigated the functional outcome of single treatment with hUC-MSCs after MCAO only. Compared with single injection, repeated administration of human umbilical cord blood-derived MSCs did not elicit significant improvements in reducing stroke injury. They proposed that elucidation of the therapeutic time window, rather than repeated administration of stem cells, would facilitate hUC-MSCs therapy in clinical application. Intravenous delivery of hUC-MSCs, in addition to induction of angiogenesis, neurogenesis, and anti-inflammatory effects, may improve the outcomes of ischemic stroke by enhancing cerebrovascular function. Of course, this needs further verification.

**CD34⁺ or CD34⁻ MSCs Equally Attenuate Neurological Injury in Stroke Rats**

Cells administered intravenously home to the site of injury through a less invasive route. However, cells delivered intravenously have the disadvantages of accumulating in the lungs and spleen, requiring high cell numbers, inducing possible systemic effects, and requiring blood–brain barrier permeability (thus limiting the time window). As shown in Fig. 2, the beneficial effects of hUC-MSCs in reducing neurological injury are not superior to those of 1 × 10⁶ hUC-MSCs. Most likely, 4 × 10⁶ hUC-MSCs delivered intravenously pass through the lungs before they are distributed throughout the body; potentially, the same numbers of cells are distributed throughout the body by injections of both 4 × 10⁶ and 1 × 10⁶ hUC-MSCs. Umbilical cord blood–derived MSCs exit the lungs faster than bone marrow–derived MSCs. A low dose of peripheral transplanted stem cells plus mannitol administration may enhance their therapeutic effects.
Figure 4. Mesenchymal stem cells therapy attenuates neuronal loss and apoptosis caused by MCAO in various brain regions of different groups of rats. (A) The upper panels depict representative antineuronal nuclei (NeuN; red) + 4,6-diamidino-2-phenylindole (DAPI; blue) or NeuN-TUNEL (green)-DAPI triple staining for sham + NS, sham + hUC-MSC 4 x 10^6, MCAO + NS, and MCAO + hUC-MSC 4 x 10^6 rats. The data are presented as the mean ± standard deviation. The values of the numbers of NeuN-TUNEL-DAPI-positive cells (B) and the numbers of colocalized NeuN- and TUNEL-positive cells (C) in the different brain regions are depicted. The data were obtained 14 d after MCAO or sham operation (n = 10 for each group). *P < 0.01, MCAO + NS group versus the sham + NS group; +P < 0.05, MCAO + hUC-MSC 4 x 10^6 group versus MCAO + NS group. Please see the defined abbreviations for the different groups in the Fig. 1 legend.
Figure 5. Mesenchymal stem cells therapy increases newly formed cells (or 5-ethynyl-2′-deoxyuridine [EdU]-positive cells) in different groups of rats. Neuronal proliferation in the frontal and parietal cortex, subventricular zone (SVZ), corpus striatum, hippocampus, and hypothalamus was evaluated by EdU (green)–antineuronal nuclei (NeuN; red)–4,6-diamidino-2-phenylindole (DAPI; blue) triple immunofluorescence staining 14 d postischemic stroke. (A) The upper panels depict representative EdU-NeuN-DAPI triple staining for sham + NS, sham + hUC-MSC 4 × 10^6, MCAO + NS, and MCAO + hUC-MSC 4 × 10^6 rats. (B) The data are presented as the mean ± standard deviation of 10 rats for each group. *P < 0.05 for the MCAO + NS group versus the sham + NS group; +P < 0.05 for the MCAO + hUC-MSC 4 × 10^6 group versus the MCAO + NS group. Please see the Fig. 1 legend for the defined group abbreviations.
Figure 6. Mesenchymal stem cells therapy stimulates the proliferation of neuroblasts in different brain regions of the different groups of rats. Neuroblast proliferation in the frontal and parietal cortex, subventricular zone (SVZ), corpus striatum, hippocampus, and hypothalamus was evaluated by 5-ethynyl-2'-deoxyuridine (EdU)–DCX (green)–4,6-diamidino-2-phenylindole (DAPI; blue) triple immunofluorescence staining 14 d postischemic stroke. (A) The upper panels depict representative EdU-DCX-DAPI triple staining for sham + NS, sham + hUC-MSC 4 × 10⁶, MCAO + NS, and MCAO + hUC-MSC 4 × 10⁶ rats. (B) The data are presented as the mean ± standard deviation values of 10 rats per group. *P < 0.05 compared with the sham + NS group; †P < 0.05 compared with the MCAO + NS group. Please see the Fig. 1 legend for the definitions of the group abbreviations.
Our hUC-MSCs were negative for the specific surface antigen CD34. Approximately 2% of human umbilical cord blood (hUCB) mononuclear cells (MNCs) are considered stem cells and a majority are CD34+ 27. In ischemic stroke rats, intravenous injections of hUCB-MNCs-CD34+ or hUCB-MNCs-CD34− cells equally reduced neurofunctional deficits and diminished lesion volume. Similarly, in the present study, intravenous injection of hUC-MSCs-CD34− improved ischemic stroke outcomes in rats. Moreover, in vitro, compared with CD34− cells, CD34+ cells can more easily home to neural tissue.36

**MSCs Attenuate Neurological Injury in Stroke Rats by Reducing the Number of Hypertrophic Microglial/Macrophages**

Microglia/macrophages in the brain undergo transformations in their morphology between ramified and hypertrophic (amoeboid) forms to maintain the homeostasis of the brain.5 In a rat model of MCAO, hypertrophic or amoeboid microglia are mainly concentrated around peri-lesioned areas,37 whereas macrophages can shift to the ischemic core.38 A reduction but not complete loss of blood flow around microglia somata induces morphological activation.59 Once activated, microglia retract their ramifications and transform into an amoeboid (or hypertrophic) morphology, which may be related to phagocytosis and proinflammatory cytokine production. Both microglia and macrophages increase phagocytic activity at 72 h after a stroke.40 Hypertrophic microglia produce relatively higher levels of reactive oxygen species and tumor necrosis factor α (TNF-α), whereas macrophages produce higher levels of interleukin-1β (IL-1β).40 Increased proinflammatory cytokines result in neuronal apoptosis.41 Indeed, as shown in the present study, all the neurological injury, hypertrophic microglia accumulation, and decreased endogenous neurogenesis occurred 14 d after MCAO in rats that received vehicle solution therapy. Our results further demonstrate that hUC-MSC therapy significantly attenuates MCAO-induced neurological injury via promoting the transformation of hypertrophic microglia with larger somata area (140 ± 11.56 μm²) into ramified microglia with smaller somata area (85 ± 9.78 μm²). However, it should be stressed that hUC-MSCs may ameliorate ischemic brain injury by inhibiting both immune cell activation within the brain and immune cell migration into the brain from the periphery.42

**MSCs Promote Newborn Neuron Migration in the Ischemic Brain by Reducing the Number of Hypertrophic Microglial/Macrophages**

The generation of newborn neurons in both the subgranular zone (SGZ) of the hippocampus and the SVZ of the lateral cerebral ventricle is attributed to the constant process of neurogenesis.43 Newly formed neuroblasts from the SGZ or SVZ migrate to where they are needed to replenish neuronal loss or apoptosis in the adult brain.44 In rats with ischemic stroke, a large number (>80%) of newly formed neurons die during the first 2 wk after the insult.45 Indeed, as shown in our present results, 2 wk after MCAO or a sham operation, sham surgeries (with or without hUC-MSC treatment) induced more newly born neurons (or NeuN+/EdU+ cells) than MCAO alone (Fig. 5). Likewise, the migration of newly formed neuroblasts (or DCX+/EdU+ cells) was lowest in MCAO animals (Fig. 6). These findings are in sharp contrast to the existing literature and common understanding.46–48 These investigators have provided convincing data that neurogenesis occurs reactively after an ischemic stroke but is rare in the steady state. However, our present hypothesis is supported by several reports. For example, physical exercise increases cell proliferation and neurogenesis, while stress reduces this type of cellular response.49,50 In MCAO rats, microglial activation is detrimental to the survival of newly formed neurons.6 Interestingly, a recent report has demonstrated that umbilical cord blood plasma shares with the hUC-MSCs the same beneficial effects in inhibiting microglial activation but stimulating neurogenesis in a stroke rat brain.51 In fact, paracrine signaling is believed to be the most important mediator of MSC therapy in brain injury.3 Again, the paracrine mechanisms mediating the beneficial effects of MSCs need to be elucidated in future work.

**Conclusions**

In summary, 14 d after MCAO, rats displayed neurological injury (evidenced by cerebral infarction, neuronal apoptosis, and neurological deficits), followed by accumulation of hypertrophic microglia/macrophages but the reduction of neuron and neuroblast migration in ipsilateral brain regions. Intravenous administration of hUC-MSCs at 24 h after MCAO resulted in a significant recovery in neurological injury, accompanied by a reduction in hypertrophic (or amoeboid) microglia/macrophage accumulation and enhancement of neuron and neuroblast migration in ipsilateral brain regions. In MCAO rats, hypertrophic microglia/macrophages were detrimental to the survival of newly formed neurons. On this basis, it appears that hUC-MSCs might improve neurological injury in ischemic stroke rats by inhibiting hypertrophic microglia/macrophage accumulation and promoting neuroblast migration.

**Author Contribution**

Authors conceived and designed the experiments (WL, CPC, MTL, and HJL), performed the experiments (TWK, CHL, and YCS), contributed reagents/materials/analysis tools (WL, YCYH, KCN, and CPC), and wrote the manuscript (MTL, CPC, and HJL).

**Ethical Approval**

This study was approved by the Institutional Animal Care and Use Committee (approval no. 104042801) at Chi Mei Medical Center.
Statement of Human and Animal Rights
When not undergoing surgery (as described in the Materials and Methods section), the rat was given postoperative care and allowed free access to food and water.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Drs. Willie Lin, Yogi Chang-Yo Hsuan, Cheng-Hsien Lin, and Yu-Chin Su are employees of Meridigen Company.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by research grants from Chi Mei Medical Center (CMFHT10504), Tainan City, Taiwan, and Meridigen Biotech Co., Ltd. (2014-RD-VIV-009), Taipei City, Taiwan.

ORCID iD
Ching-Ping Chang https://orcid.org/0000-0003-0890-9414

References
1. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40(7):2438–2441.
2. Whiteley WN, Slot KB, Fernandes P, Sandercoc P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43(11):2904–2909.
3. Hsuan YC, Lin CH, Chang CP, Lin MT. Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke. Brain Behav. 2016;6(10):e00526.
4. McGuckin CP, Jurga M, Miller AM, Samrowska A, Wiedner M, Boyle NT, Lynch MA, Jablonska A, Drela K, Lukomska B, et al. Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Arch Biochem Biophys. 2013;534(1-2):88–97.
5. Xiong XY, Liu L, Yang QW. Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. Prog Neurobiol. 2016;142:23–44.
6. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience. 2009;158(3):1021–1029.
7. Jin Q, Cheng J, Liu Y, Wu J, Wang X, Wei S, Zhou X, Qin Z, Jia J, Zhen X. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun. 2014;40:131–42.
8. Graciarena M, Roca V, Mathieu P, Depino AM, Pitossi FJ. Differential vulnerability of adult neurogenesis by adult and prenatal inflammation: role of TGF-beta1. Brain Behav Immun. 2013;34:17–28.
9. Mouihate A. TLR4-mediated brain inflammation halts neurogenesis: impact of hormonal replacement therapy. Front Cell Neurosci. 2014;8:146.
10. Resende FF, Bai X, Del Bel EA, Kirchhoff F, Scheller A, Titze-de-Almeida R. Evaluation of TgH(CX3CR1-EGFP) mice implanted with mCherry-GL261 cells as an in vivo model for morphometrical analysis of glioma-microglia interaction. BMC Cancer. 2016;16:72.
11. Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-alpha contents and by stimulating newly formed neurogenesis. Mediators Inflamm. 2013;2013:620837.
12. Couillard-Despres S, Winner B, Schaubek S, Aigner R, Vroemen M, Weidner N, Bogdahn U, Winkler J, Kuhn HG, Aigner L. Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci. 2005;21(1):1–14.
13. Zhang RL, Zhang ZG, Zhang L, Chopp M. Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia. Neuroscience. 2001;105(1):33–41.
14. Wu MH, Huang CC, Chio CC, Tsai KJ, Chang CP, Lin NK, Lin MT. Inhibition of peripheral TNF-alpha and downregulation of microglial activation by alpha-lipoic acid and etanercept protect rat brain against ischemic stroke. Mol Neurobiol. 2016;53(7):4961–4971.
15. Chen SF, Hsu CW, Huang WH, Wang JY. Post-injury baicailein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. Br J Pharmacol. 2008;155(8):1279–1296.
16. Chang MW, Young MS, Lin MT. An inclined plane system with microcontroller to determine limb motor function of laboratory animals. J Neurosci Methods. 2008;168(1):186–194.
17. Bouet V, Fretet T, Toutain J, Divoux D, Boulourd M, Schumann-Bard P. Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurol. 2007;203(2):555–567.
18. Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G. Behavioral tests after intracerebral hemorrhage in the rat. Stroke. 2002;33(10):2478–2484.
19. Tsai MC, Chang CP, Peng SW, Jhuang KS, Fang YH, Lin MT, Tsao TC. Therapeutic efficacy of neuro Aid (MLC 601), a traditional Chinese medicine, in experimental traumatic brain injury. J Neuroimmun Pharmacol. 2015;10(1):45–54.
20. Schaar KL, Brenneman MM, Savitz SI. Functional assessments in the rodent stroke model. Exp Transl Stroke Med. 2010;2(1):13.
21. Ding Y, Li J, Lai Q, Rafols JA, Luan X, Clark J, Diaz FG. Motor balance and coordination training enhances functional outcome in rat with transient middle cerebral artery occlusion. Neuroscience. 2004;123(3):667–674.
22. Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin MT. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin Sci (Lond). 2013;124(3):165–176.
28. Park HW, Kim Y, Chang JW, Yang YS, Oh W, Lee JM, Park HR, Kim DG, Paek SH. Effect of single and double administration of human umbilical cord blood-derived mesenchymal stem cells following focal cerebral ischemia in rats. Exp Neurol. 2017;26(1):55–65.

29. Cui Y, Ma S, Zhang C, Cao W, Liu M, Li D, Lv P, Xing Q, Qu R, Yao N, et al. Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer’s disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis. Behav Brain Res. 2017;320:291–301.

30. Liao W, Zhong J, Lu J, Ciceri MR, Misra V, Duong TQ. Intraarterial transplantation of human umbilical cord blood mononuclear cells in intracerebral hemorrhage rat: implications of anti-inflammation and angiogenesis. Cell Physiol Biochem. 2009;24(3–4):307–316.

31. Huang L, Liu Y, Lu J, Cerqueira B, Misra V, Duong TQ. Intraarterial transplantation of human umbilical cord blood mononuclear cells in hyperacute stroke improves vascular function. Stem Cell Res Ther. 2017;8(1):74.

32. Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int. 2013;2013:732742.

33. Boltze J, Arnold A, Walczak P, Jolkkonen J, Cui L, Wagner DC. The dark side of the force—constraints and complications of cell therapies for stroke. Front Neurol. 2015;6:155.

34. Nystedt J, Anderson H, Tikkkanen J, Peltola M, Hirvonen T, Takalo R, Heikkinen A, Satomaa T, Natunen S, Lehtonen S, et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells. 2013;31(2):317–326.

35. Tajiri N, Lee JY, Acosta S, Sanberg PR, Borlongan CV. Breaking the blood-brain barrier with mannitol to aid stem cell therapeutics in the chronic stroke brain. Cell Transplant. 2016;25(8):1453–1460.

36. Boltze J, Reich DM, Hau S, Reymann KG, Sanberg PR, Lobsien D, Wagner DC, Kamprad M, Stahl T. Assessment of neuroprotective effects of human umbilical cord blood mononuclear cell subpopulations in vitro and in vivo. Cell Transplant. 2012;21(4):723–737.

37. Gelosa P, Lecca D, Fumagalli M, Wypych D, Pignieri A, Cimino M, Verderio C, Enerback M, Nikookhesal E, Tremoli E, et al. Microglia is a key player in the reduction of stroke damage promoted by the new anti-thrombotic agent ticagrelor. J Cereb Blood Flow Metab. 2014;34(6):979–988.

38. Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A, Sica A. Hypoxia-mediated regulation of macrophage functions in pathophysiology. Int Immunol. 2013;25(2):67–75.

39. Masuda T, Croom D, Hida H, Kirov SA. Capillary blood flow around microglial somata determines dynamics of microglial processes in ischemic conditions. Glia. 2011;59(11):1744–1753.

40. Ritzel RM, Patel AR, Grenier JM, Crapser J, Verma R, Jellison ER, McCullough LD. Functional differences between microglia and monocytes after ischemic stroke. J Neuroinflammation. 2015;12:106.

41. Macchi B, Di Paola R, Marino-Merlo F, Felice MR, Cuzzocrea S, Mastino A. Inflammatory and cell death pathways in brain and peripheral blood in Parkinson’s disease. CNS Neurol Drug Targets. 2015;14(3):313–324.

42. Hocum Stone LL, Xiao F, Rotschafer J, Nan Z, Juliano M, Sanberg CD, Sanberg PR, Kuzmin-Nichols N, Grande A, Cheeran MC, et al. Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells: mechanisms of action. Cell Transplant. 2016;25(8):1473–1488.

43. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132(4):645–660.

44. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crossstalk in CNS diseases. Neuroscience. 2009;158(3):1122–1132.

45. Arvidsson A, Collin T, Kikirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med. 2002;8(9):963–970.

46. Ziemk-Malecz M, Zalewska T. Endogenous neurogenesis induced by ischemic brain injury or neurodegenerative diseases in adults. Acta Neurobiol Exp (Wars). 2012;72(4):309–324.

47. Yamashita T, Abe K. Endogenous neurogenesis, oligodendrogenesis and angiogenesis after ischemic brain injury. J Neurol Neurosurg Psychiatry. 2012;83(9):963–970.

48. Herrmann DM, Peruzzotti-Jametti L, Schlechter J, Bernstock JD, Doeppner TR, Pluchino S. Neural precursor cells in the ischemic brain—integration, cellular crosstalk, and consequences for stroke recovery. Front Cell Neurosci. 2014;8:291.